NewLink Genetics Corporation (NASDAQ:NLNK)‘s stock had its “buy” rating reaffirmed by research analysts at Cantor Fitzgerald in a research note issued on Friday. They presently have a $26.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 47.14% from the company’s current price.

The analysts wrote, “Incremental Data Points in the Right Direction. Updated data from the Phase I/II trial in advanced melanoma (excluding ocular melanoma), showed improving complete responses (CRs) to 20% vs. 12% reported at six months. The overall response rate (ORR) and disease control rate (DCR) were stable at 61% and 80%, respectively, vs. 59% and 80% at six months.””

Several other research firms have also recently weighed in on NLNK. Robert W. Baird reissued an “outperform” rating and issued a $25.00 price objective on shares of NewLink Genetics Corporation in a research report on Monday, June 5th. ValuEngine raised NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a research report on Friday, May 19th. Zacks Investment Research cut NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $18.00 price objective on shares of NewLink Genetics Corporation in a research report on Monday, May 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. NewLink Genetics Corporation has an average rating of “Buy” and an average target price of $24.17.

NewLink Genetics Corporation (NASDAQ NLNK) traded down 6.8715% during midday trading on Friday, reaching $16.4558. The company had a trading volume of 7,547,167 shares. NewLink Genetics Corporation has a 12-month low of $5.90 and a 12-month high of $25.17. The stock’s 50 day moving average is $7.52 and its 200 day moving average is $12.82. The firm’s market capitalization is $484.15 million.

NewLink Genetics Corporation (NASDAQ:NLNK) last posted its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. The business had revenue of $10.37 million for the quarter, compared to analysts’ expectations of $2.65 million. Equities research analysts expect that NewLink Genetics Corporation will post ($2.82) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “NewLink Genetics Corporation (NLNK) Earns Buy Rating from Cantor Fitzgerald” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/10/newlink-genetics-corporation-nlnk-rating-reiterated-by-cantor-fitzgerald.html.

Institutional investors and hedge funds have recently modified their holdings of the business. First Mercantile Trust Co. bought a new stake in shares of NewLink Genetics Corporation in the first quarter valued at $143,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of NewLink Genetics Corporation in the first quarter valued at $145,000. Brandes Investment Partners LP bought a new stake in shares of NewLink Genetics Corporation in the first quarter valued at $221,000. UBS Asset Management Americas Inc. bought a new stake in shares of NewLink Genetics Corporation in the first quarter valued at $297,000. Finally, Teza Capital Management LLC bought a new stake in shares of NewLink Genetics Corporation in the first quarter valued at $312,000. Hedge funds and other institutional investors own 54.78% of the company’s stock.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Stock Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related stocks with our FREE daily email newsletter.